相关实验视频

药物坚持:它对心血管结果的重要性

P Michael Ho¹, Chris L Bryson, John S Rumsfeld

¹Denver VA Medical Center, Denver, CO, USA. michael.ho@va.gov

|June 17, 2009

概括

药物不服药是常见的,与健康状况不佳和成本增加有关. 改善患者遵守要求了解测量,流行,原因和干预措施.

科学领域:

医疗保健服务研究医疗服务研究
临床药房临床药房
患者坚持性研究的研究.

背景情况:

药物坚持,包括正确的剂量和持续治疗,对于有效的治疗至关重要.
药物不服药是一个重大挑战,导致不良健康结果和不断增加的医疗保健支出.
目前的临床实践很少测量患者的药物服药程度或实施改善药物服药的干预措施.

研究的目的:

审查测量药物服药能力的方法.
检查药物不服药的患病率和原因.
探索不遵守和患者结果之间的联系,并讨论改善的干预措施.

主要方法:

关于粘附度测量技术的文献综述.
对药物不服药的流行数据的分析.
综合研究关于不遵守对健康结果的影响.
审查发现的不遵守的原因.
基于证据的干预措施的汇编,以提高药物坚持.

主要成果:

测量药物坚持存在各种方法,尽管它们在实践中的使用是有限的.
药物不服药在各种患者群体和治疗领域中普遍存在.
不遵守与较差的临床结果和增加的医疗保健成本密切相关.
多种因素导致不遵守,包括患者相关,药物相关和医疗保健系统相关的问题.
一系列干预措施,从行为策略到技术解决方案,可以改善药物坚持.

结论:

解决不服药问题对于改善患者的治疗结果和降低医疗保健成本至关重要.
需要系统的测量和有针对性的干预措施,以提高在常规临床实践中的药物坚持.
进一步的研究应该集中在优化坚持干预措施和将其整合到标准护理途径中.

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...